JUST IN
You are here » Home » Companies » Company Overview » Themis Medicare Ltd

Themis Medicare Ltd.

BSE: 530199 Sector: Health care
NSE: THEMISMED ISIN Code: INE083B01016
BSE 00:00 | 05 Jul 768.00 15.95
(2.12%)
OPEN

764.15

 HIGH

768.00

 LOW

764.00
NSE 00:00 | 05 Jul 766.35 11.40
(1.51%)
OPEN

769.00

 HIGH

772.00

 LOW

741.85
Add to Watchlist  |   Add to Portfolio
OPEN 764.15
PREVIOUS CLOSE 752.05
VOLUME 76
52-Week high 1198.80
52-Week low 659.65
P/E 11.48
Mkt Cap.(Rs cr) 707
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00
OPEN 764.15
CLOSE 752.05
VOLUME 76
52-Week high 1198.80
52-Week low 659.65
P/E 11.48
Mkt Cap.(Rs cr) 707
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00

Themis Medicare Ltd. (THEMISMED) - Company History

Incorporated in 1969 Themis Medicare Ltd. formerly known as Themis Chemicals (TCL) was originally promoted by Chemosyn and Medimpex but was taken over by a group consisting of Shantibhai D Patel and K T Lakdawala who also have interests in Andhra Synthetics and Antibiotics which was merged with Artemis Pharmaceuticals in April 93.In Mar.'95 the company came out with a public issue equity shares (premium : Rs 110) to finance the expansion-cum-modernisation of its synthetic bulk drug plant at Vapi the setting up of a formulation unit at Lilora Baroda as backward integration and to augment long-term working capital.Total cost of the project was estimated at Rs 17.64 cr. TCL manufactures and sells synthetic bulk drugs and formulations. It operates in the therapeutic segments of anti-tuberculosis cerebroactivators bronchodilators anti-asthmatic anaesthetic and other segments.Anti-tuberculosis bulk drugs and formulations account for 60% of its turnover and the company is rated fourth in terms of turnover in this segment. TCL has also started manufacturing and exporting fumagillin an anti-bacterial drug for veterinary use for which it has a confirmed buy-back arrangement with Chinoin Hungary.The company with the help of M/s PharmogradMoscow a manufacturing unit is planning to market its Anti-T.B.formulation products through the collborators throughout the Russian Federation for tradetenders and govt.supplies.

Browse STOCK Companies

Quick Links for Themis Medicare:

.